1. Genomic signatures in pediatric advanced stage Burkitt lymphoma/leukemia in a Chinese population detected by next generation sequencing
- Author
-
Yuxia Guo, Jianwen Xiao, Nange Yin, Xiaoying Lei, Ling Song, and Jin Zhu
- Subjects
Chinese population ,business.industry ,Advanced stage ,Medicine ,General Medicine ,Computational biology ,Burkitt lymphoma/leukemia ,business ,DNA sequencing ,Exome sequencing ,respiratory tract diseases - Abstract
Background: Burkitt lymphoma/leukemia (BL/BAL) is the most common lymphoma in children, and the sporadic subtype is dominant in Chinese populations. MYC gene translocations are essential for sporadic BL/BAL (sBL/BAL), but other gene mutations also play important roles in the development of sBL/BAL. Methods: The clinical data of ten Chinese children with sBL/BAL were collected, and next generation sequencing of their tumor tissues was conducted. Cases of BL and diffuse large B cell lymphoma (DLBCL) were also collected from a database, and bioinformatics analysis was conducted.Results: Nine boys and one girl were enrolled in the study, including six BL patients (stage III) and four BAL patients (stage IV). The average age at diagnosis was 100.10±13.39m; overexpression of CD20 was detectable, and MYC rearrangements were confirmed. The patients received combination treatment of chemotherapy and rituximab. All patients achieved complete remission and survived. Germline causal gene mutations were detected in four (40%) patients by whole-exome sequencing (WES); ID3, BRCA2, ARID1A and SMARCA4 mutations, in addition to MYC mutations, were the most common somatic mutations. The gene functions in etiology were different between the BL and DLBCL datasets. The identified mutated genes were enriched and connected by GO or KEGG pathways, and it seemed that the PI3K-Akt signaling pathway or the EGFR-TKI resistance pathway played important roles in the etiology of sBL/BAL. Conclusion: sBL/BAL is a highly aggressive but curable lymphoma; its etiology and pathology require additional research. The molecular hallmark of sBL/BAL is MYC translocation, whereas additional chromosomal abnormalities and gene mutations also occur and play roles in the progression of the disease. The PI3K-Akt signaling pathway seems to play important roles in the development of sBL/BAL, and sBL/BAL may be inhibited by this signaling pathway. The EGFR-TKI resistance pathway was also analyzed in sBL/BAL patients, revealing that EGFR-TKI treatment is invalid in this disease. Further research is needed for hypothesis development and possible mechanism discovery.
- Published
- 2021
- Full Text
- View/download PDF